Evidence map›Paper›PMID 38258557›Full record

ArticleFuture oncology (London, England)2024

The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations.

William Wong, Stacey Kowal, Tu My To, Achal Patel, David Veenstra, Louis Garrison, Meng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Responses to Commentaries on "Ethics as if Your Life Depended on It".Journal of empirical research on human research ethics : JERHRE · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

William WongGenentech, Inc., South San Francisco, CA 94080, USA.ORCID 0000-0002-6054-278X
Stacey KowalGenentech, Inc., South San Francisco, CA 94080, USA.ORCID 0000-0001-6018-6052
Tu My ToGenentech, Inc., South San Francisco, CA 94080, USA.ORCID 0000-0001-9506-7539
Achal PatelGenentech, Inc., South San Francisco, CA 94080, USA.
David VeenstraDepartment of Pharmacy, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-0687-0480
Louis GarrisonDepartment of Pharmacy, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0002-9468-4989
Meng LiDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-8537-7872

Funding

Genentech Inc.Genentech, Inc.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug ApprovalAgedFemaleHumansMaleMiddle AgedNeoplasmsTime FactorsTreatment OutcomeUnited Statesaccelerated approvalscancerinnovationreal option valuereal-world datatherapeutic bridging

Identifiers

PMID38258557
PMCPMC11721754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.